A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Public ClinicalTrials.gov record NCT01695044. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-label, Multicenter Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
PSMA ADC 2301 is a Phase 2, open-label, study to assess the anti-tumor activity and tolerability of Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) in two groups of subjects with metastatic castration-resistant prostate cancer (mCRPC). One group comprises subjects who must have received at least one taxane-containing chemotherapy regimen (e.g. docetaxel, cabazitaxel). The second group comprises subjects who are cytotoxic chemotherapy-naïve. Subjects who are cytotoxic chemotherapy-naïve must have received and progressed on-, be ineligible for, refused, have an intolerance to-, or not have access to Radium-223. Both groups of subjects must also have received and progressed on abiraterone acetate and/or enzalutamide. If a subject is unable to receive abiraterone acetate and/or enzalutamide, Sponsor approval is required for participation in the study. Subjects will receive up to eight doses of PSMA ADC approximately once every three weeks.
Study identification
- NCT ID
- NCT01695044
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 119 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2012
- Primary completion
- Sep 30, 2014
- Completion
- Jan 31, 2015
- Last update posted
- Mar 23, 2017
2012 – 2015
United States locations
- U.S. sites
- 36
- U.S. states
- 25
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35205 | — |
| Not listed | Tucson | Arizona | 85724 | — |
| Not listed | Burbank | California | 91505 | — |
| Not listed | Encinitas | California | 92024 | — |
| Not listed | Los Angeles | California | 90024 | — |
| Not listed | San Diego | California | 92123 | — |
| Not listed | Denver | Colorado | 80218 | — |
| Not listed | New Haven | Connecticut | 06520 | — |
| Not listed | Norwalk | Connecticut | 06856 | — |
| Not listed | Port Saint Lucie | Florida | 34952 | — |
| Not listed | Honolulu | Hawaii | 96819 | — |
| Not listed | Fairway | Kansas | 66205 | — |
| Not listed | New Orleans | Louisiana | 70115 | — |
| Not listed | Baltimore | Maryland | 21201 | — |
| Not listed | Baltimore | Maryland | 21205 | — |
| Not listed | Rockville | Maryland | 20850 | — |
| Not listed | Boston | Massachusetts | 02111 | — |
| Not listed | Ann Arbor | Michigan | 28109 | — |
| Not listed | Rochester | Minnesota | 55905 | — |
| Not listed | Omaha | Nebraska | 68130 | — |
| Not listed | Las Vegas | Nevada | 89169 | — |
| Not listed | Lake Success | New York | 11042 | — |
| Not listed | New York | New York | 10065 | — |
| Not listed | Rochester | New York | 14642 | — |
| Not listed | Stony Brook | New York | 11794 | — |
| Not listed | Huntersville | North Carolina | 28078 | — |
| Not listed | Raleigh | North Carolina | 27607 | — |
| Not listed | Cleveland | Ohio | 44195 | — |
| Not listed | Pittsburgh | Pennsylvania | 15232 | — |
| Not listed | Providence | Rhode Island | 02906 | — |
| Not listed | Greenville | South Carolina | 29605 | — |
| Not listed | Myrtle Beach | South Carolina | 29572 | — |
| Not listed | Memphis | Tennessee | 38120 | — |
| Not listed | Dallas | Texas | 75390 | — |
| Not listed | Norfolk | Virginia | 23502 | — |
| Not listed | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01695044, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 23, 2017 · Synced Sep 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01695044 live on ClinicalTrials.gov.